

Lipika Goyal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7074516/publications.pdf>

Version: 2024-02-01

131
papers

7,793
citations

87888

38
h-index

56724

83
g-index

135
all docs

135
docs citations

135
times ranked

8905
citing authors

#	ARTICLE	IF	CITATIONS
1	Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGFR Aberrations: A Phase I Dose-Expansion Study. <i>Cancer Discovery</i> , 2022, 12, 402-415.	9.4	119
2	Mutant IDH Inhibits IFN-3 TET2 Signaling to Promote Immuno-evasion and Tumor Maintenance in Cholangiocarcinoma. <i>Cancer Discovery</i> , 2022, 12, 812-835.	9.4	55
3	A multicenter, observational, phase 4 study (STELLAR) to evaluate the safety and tolerability of lenvatinib (LEN) in patients with advanced or unresectable hepatocellular carcinoma (uHCC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS485-TPS485.	1.6	1
4	Reverse Transcriptase Inhibition Disrupts Repeat Element Life Cycle in Colorectal Cancer. <i>Cancer Discovery</i> , 2022, 12, 1462-1481.	9.4	30
5	EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma. <i>Cancer Discovery</i> , 2022, 12, 1378-1395.	9.4	33
6	PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib versus gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma with an FGFR2 gene fusion/rearrangement.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4171-TPS4171.	1.6	6
7	Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR fusions/rearrangements.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4009-4009.	1.6	33
8	Changes in Functional Assessment of Cancer Therapy: General (FACT-G) to predict treatment response and survival outcomes in patients with metastatic gastrointestinal (GI) cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 6570-6570.	1.6	0
9	Design and rationale of a first-in-human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible (irrev), pan-FGFR inhibitor (FGFRi), in adult patients with solid tumors harboring FGFR2 and/or FGFR3 gene alterations (NCT05242822).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS9601-TPS9601.	1.6	0
10	Associations of baseline patient-reported outcomes with treatment outcomes in advanced gastrointestinal cancer. <i>Cancer</i> , 2021, 127, 619-627.	4.1	7
11	The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients. <i>Oncologist</i> , 2021, 26, e1036-e1049.	3.7	30
12	Phase III study of NUC-1031 + cisplatin vs gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS351-TPS351.	1.6	3
13	Circulating Tumor DNA Predicts Pathologic and Clinical Outcomes Following Neoadjuvant Chemoradiation and Surgery for Patients With Locally Advanced Rectal Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 123-132.	3.0	30
14	A phase II study of atezolizumab (ATEZO) and bevacizumab (Bev) in combination with Y90 TARE in patients (Pts) with hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS358-TPS358.	1.6	3
15	Case 8-2021: A 34-Year-Old Woman with Cholangiocarcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 1054-1064.	27.0	2
16	FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma. <i>Cancer Discovery</i> , 2021, 11, 2488-2505.	9.4	46
17	Targeting FGFR inhibition in cholangiocarcinoma. <i>Cancer Treatment Reviews</i> , 2021, 95, 102170.	7.7	85
18	First-in-human study of highly selective FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4165-TPS4165.	1.6	11

#	ARTICLE	IF	CITATIONS
19	Cell-free DNA captures tumor heterogeneity and driver alterations in rapid autopsies with pre-treated metastatic cancer. <i>Nature Communications</i> , 2021, 12, 3199.	12.8	33
20	Changes in patient-reported outcomes (PROs) and tumor markers (TMs) to predict treatment response and survival outcomes in patients with metastatic gastrointestinal (GI) cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 6560-6560.	1.6	0
21	Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16253-e16253.	1.6	0
22	Treatment of Gemcitabine-Induced Thrombotic Microangiopathy Followed by Gemcitabine Rechallenge With Eculizumab. <i>Kidney International Reports</i> , 2021, 6, 1464-1468.	0.8	9
23	FOENIX-CCA2 quality of life data for futibatinib-treated intrahepatic cholangiocarcinoma (iCCA) patients with <i>FGFR2</i> fusions/rearrangements.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4097-4097.	1.6	4
24	Clinical and mutational profile of ARID1A-mutated gastrointestinal cancers: Duration of response to platinum-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, e15611-e15611.	1.6	1
25	Phase III study of NUC-1031 + cisplatin versus gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4164-TPS4164.	1.6	1
26	Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant- <i>IDH1</i> cholangiocarcinoma. <i>Future Oncology</i> , 2021, 17, 2057-2074.	2.4	14
27	Abstract CT010: Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with <i>FGFR2</i> fusions/rearrangements. <i>Cancer Research</i> , 2021, 81, CT010-CT010.	0.9	28
28	Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes. <i>Pancreatology</i> , 2021, 21, 1119-1126.	1.1	13
29	P024â€œ...KEYNOTE-937 trial in progress: adjuvant pembrolizumab for hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation. , 2021, , .		1
30	Paving a pathway for drug development in HER2-positive biliary tract cancer. <i>Lancet Oncology</i> , The, 2021, 22, 1204-1206.	10.7	0
31	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. , 2021, 9, e002794.		43
32	Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With <i>IDH1</i> Mutation. <i>JAMA Oncology</i> , 2021, 7, 1669.	7.1	194
33	Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with <i>FGFR2</i> fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 803-815.	8.1	205
34	Changes in patient-reported outcomes (PROs) and tumor markers (TMs) to predict treatment response and survival in patients with metastatic gastrointestinal (GI) cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 154-154.	1.6	0
35	Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an <i>FGFR2</i> gene fusion or rearrangement.. <i>Journal of Clinical Oncology</i> , 2021, 39, 265-265.	1.6	70
36	Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 541-565.	4.9	477

#	ARTICLE	IF	CITATIONS
37	Combining systemic and local therapies for hepatocellular carcinoma. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 976-978.	8.1	2
38	Integration of Systemic and Liver-Directed Therapies for Locally Advanced Hepatocellular Cancer: Harnessing Potential Synergy for New Therapeutic Horizons. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 567-576.	4.9	4
39	Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. <i>Nature Cancer</i> , 2021, 2, 1124-1135.	13.2	112
40	Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	56
41	Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2020, 38, 433-444.	2.6	69
42	Cholangiolar pattern and albumin in situ hybridisation enable a diagnosis of intrahepatic cholangiocarcinoma. <i>Journal of Clinical Pathology</i> , 2020, 73, 23-29.	2.0	14
43	Management implications of fluorodeoxyglucose positron emission tomography/magnetic resonance in untreated intrahepatic cholangiocarcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1871-1884.	6.4	32
44	Palliative External Beam Radiation Therapy for Hepatocellular Carcinoma With Right Atrial Tumor Thrombus. <i>Practical Radiation Oncology</i> , 2020, 10, e183-e187.	2.1	2
45	A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer. <i>Investigational New Drugs</i> , 2020, 38, 1533-1539.	2.6	13
46	Hypofractionated Radiation Therapy for Unresectable/Locally Recurrent Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 1122-1129.	1.5	29
47	Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma. , 2020, 8, e001435.		87
48	Patterns of Failure and the Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation. <i>Annals of Surgical Oncology</i> , 2020, 27, 5161-5172.	1.5	4
49	Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6158-6167.	7.0	37
50	Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClariDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2020, 21, 796-807.	10.7	620
51	Randomized trial of a hospice video educational tool for patients with advanced cancer and their caregivers. <i>Cancer</i> , 2020, 126, 3569-3578.	4.1	6
52	Targets for therapy in biliary tract cancers: the new horizon of personalized medicine. <i>Chinese Clinical Oncology</i> , 2020, 9, 7-7.	1.2	4
53	Infigratinib in patients with advanced cholangiocarcinoma with <i>FGFR2</i> gene fusions/translocations: the PROOF 301 trial. <i>Future Oncology</i> , 2020, 16, 2375-2384.	2.4	62
54	Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 1877-1885.	7.0	67

#	ARTICLE	IF	CITATIONS
55	Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 161-173.	3.8	7
56	FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring <i>FGFR2</i> gene fusions or other rearrangements.. Journal of Clinical Oncology, 2020, 38, 108-108.	1.6	61
57	Final results from the phase I study expansion cohort of the selective FGFR inhibitor Debio 1,347 in patients with solid tumors harboring an FGFR gene fusion.. Journal of Clinical Oncology, 2020, 38, 3603-3603.	1.6	23
58	A retrospective analysis of post second-line chemotherapy treatment outcomes for patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions.. Journal of Clinical Oncology, 2020, 38, 4591-4591.	1.6	5
59	A pilot study of durvalumab/tremelimumab (durva/treme) and radiation (XRT) for metastatic biliary tract cancer (mBTC): Preliminary safety and efficacy.. Journal of Clinical Oncology, 2020, 38, 547-547.	1.6	10
60	Therapeutic targeting of extracellular FGFR2 activating deletions in intrahepatic cholangiocarcinoma.. Journal of Clinical Oncology, 2020, 38, 567-567.	1.6	1
61	Phase Ib study of gemcitabine, nab-paclitaxel, and ficlatuzumab in patients with advanced pancreatic cancer.. Journal of Clinical Oncology, 2020, 38, 693-693.	1.6	4
62	NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121). Future Oncology, 2020, 16, 1069-1081.	2.4	15
63	The role of circulating tumor DNA (ctDNA), tumor markers (TMs), and patient-reported outcomes (PROs) in predicting treatment response in patients with metastatic gastrointestinal (GI) cancer.. Journal of Clinical Oncology, 2020, 38, 833-833.	1.6	0
64	NUC-1031 in combination with cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).. Journal of Clinical Oncology, 2020, 38, TPS602-TPS602.	1.6	2
65	Comparing clinicopathologic feature and treatment outcome of patients who underwent surgical resection or liver transplant for nonalcoholic fatty liver disease (NAFLD)-related and non-NAFLD related hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2020, 38, e16675-e16675.	1.6	0
66	A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mutant solid tumors: Safety and efficacy as single agent.. Journal of Clinical Oncology, 2020, 38, e16643-e16643.	1.6	3
67	Comparison of the clinical features, treatment patterns, and tumor mutations of patients with intrahepatic (ICC) and extrahepatic (ECC) cholangiocarcinoma.. Journal of Clinical Oncology, 2020, 38, 580-580.	1.6	0
68	Phase II study of lamivudine in p53 mutant metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2020, 38, 149-149.	1.6	2
69	Clinical and genomic factors associated with outcome following ablative radiotherapy for oligometastatic and oligoprogressive liver tumors.. Journal of Clinical Oncology, 2020, 38, 515-515.	1.6	3
70	Circulating free DNA (cfDNA) and tissue next-generation sequencing analysis in a phase II study of infigratinib (BGJ398) for cholangiocarcinoma with FGFR2 fusions.. Journal of Clinical Oncology, 2020, 38, 579-579.	1.6	1
71	Use of patient-reported outcomes (PROs) to predict treatment outcomes in patients with advanced cancer.. Journal of Clinical Oncology, 2020, 38, 186-186.	1.6	0
72	Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. The Lancet Gastroenterology and Hepatology, 2019, 4, 711-720.	8.1	161

#	ARTICLE	IF	CITATIONS
73	Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. <i>Nature Medicine</i> , 2019, 25, 1415-1421.	30.7	359
74	Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer. <i>JAMA Oncology</i> , 2019, 5, 1020.	7.1	353
75	Another Treatment Option for Advanced Hepatocellular Carcinoma With Portal Vein Thrombosis in China. <i>JAMA Oncology</i> , 2019, 5, 938.	7.1	2
76	Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma: Breakthroughs, Toxicities, and Future Frontiers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 248-260.	3.8	8
77	TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. <i>Cancer Discovery</i> , 2019, 9, 1064-1079.	9.4	254
78	Protons versus Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 64-72.	0.8	99
79	FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial. <i>Cancer</i> , 2019, 125, 2213-2221.	4.1	14
80	Patterns of Care and Outcomes of Definitive External Beam Radiotherapy and Radioembolization for Localized Hepatocellular Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 564-572.	1.3	0
81	A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 80-89.	7.0	62
82	The Tipping Point: Key Oncologic Imaging Findings Resulting in Critical Changes in the Management of Malignant Tumors of the Gastrointestinal Tract. <i>Current Problems in Diagnostic Radiology</i> , 2019, 48, 61-74.	1.4	2
83	Clinical and molecular features of patients with cholangiocarcinoma harboring FGFR genetic alterations.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4084-4084.	1.6	5
84	Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4087-4087.	1.6	42
85	FUZE clinical trial: a phase 2 study of Debio 1347 in FGFR fusion-positive advanced solid tumors irrespectively of tumor histology.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS3157-TPS3157.	1.6	18
86	Changes in alpha-fetoprotein (AFP) and systemic therapy outcomes in advanced hepatocellular carcinoma (HCC): A multicenter retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 346-346.	1.6	1
87	Hypofractionated radiation therapy for unresectable/locally recurrent intrahepatic cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 412-412.	1.6	1
88	Using circulating tumor DNA (ctDNA) to predict surgical outcome and postoperative recurrence following neoadjuvant chemoradiation (CRT) for borderline resectable/locally advanced rectal cancer (LARC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 562-562.	1.6	2
89	FOENIX-101: A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS468-TPS468.	1.6	6
90	Dose intensity of neoadjuvant FOLFIRINOX (FFX) in borderline and locally advanced pancreatic cancer (LAPC): A comparison to the adjuvant benchmark.. <i>Journal of Clinical Oncology</i> , 2019, 37, 392-392.	1.6	2

#	ARTICLE	IF	CITATIONS
91	Frequency and feasibility of detecting FGFR mRNA expression in archival samples of patients with cholangiocarcinoma (CCA).. Journal of Clinical Oncology, 2019, 37, 281-281.	1.6	0
92	Patterns of care and outcomes of definitive external beam radiotherapy and radioembolization for localized hepatocellular carcinoma: A propensity score-adjusted analysis.. Journal of Clinical Oncology, 2019, 37, 329-329.	1.6	0
93	External beam radiotherapy for hepatocellular carcinoma with right atrium tumor thrombus.. Journal of Clinical Oncology, 2019, 37, 328-328.	1.6	1
94	Aggressiveness of care and overall survival in young metastatic colorectal cancer patients.. Journal of Clinical Oncology, 2019, 37, 3563-3563.	1.6	2
95	Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma. JAMA Oncology, 2018, 4, 963.	7.1	426
96	Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. Journal of Clinical Oncology, 2018, 36, 276-282.	1.6	524
97	Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis. Cancer Medicine, 2018, 7, 2934-2942.	2.8	21
98	Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma. CardioVascular and Interventional Radiology, 2018, 41, 1799-1802.	2.0	45
99	Liver reirradiation for patients with hepatocellular carcinoma and liver metastasis. Practical Radiation Oncology, 2018, 8, 414-421.	2.1	17
100	Potentially curative combination of TGF-b1 inhibitor losartan and FOLFIRINOX (FFX) for locally advanced pancreatic cancer (LAPC): R0 resection rates and preliminary survival data from a prospective phase II study.. Journal of Clinical Oncology, 2018, 36, 4116-4116.	1.6	9
101	Phase Ib study of neoadjuvant chemoradiation (CRT) with midostaurin, 5-fluorouracil (5-FU) and radiation (XRT) for locally advanced rectal cancer: Sensitization of RAS mutant tumors.. Journal of Clinical Oncology, 2018, 36, e15674-e15674.	1.6	7
102	Using circulating tumor DNA (ctDNA) to predict surgical outcome after neoadjuvant chemoradiation for locally advanced pancreatic cancer (LAPC).. Journal of Clinical Oncology, 2018, 36, 272-272.	1.6	7
103	Preoperative chemoradiotherapy versus postoperative chemoradiotherapy for local advanced gastric or Siewert II/III GEJ cancer: A retrospective analysis.. Journal of Clinical Oncology, 2018, 36, 115-115.	1.6	0
104	An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 1123-1128.	7.1	133
105	A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. Cancer, 2017, 123, 1979-1988.	4.1	92
106	Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype. Journal of the National Cancer Institute, 2017, 109, .	6.3	82
107	Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. Cancer Discovery, 2017, 7, 252-263.	9.4	384
108	New Horizons for Precision Medicine in Biliary Tract Cancers. Cancer Discovery, 2017, 7, 943-962.	9.4	419

#	ARTICLE	IF	CITATIONS
109	FOLFIRINOX (F-NOX) followed by individualized radiation for borderline-resectable pancreatic cancer: Preliminary toxicity and R0 resection rates from a prospective phase II study.. Journal of Clinical Oncology, 2017, 35, 368-368.	1.6	1
110	TGF-B1 inhibition with losartan in combination with FOLFIRINOX (F-NOX) in locally advanced pancreatic cancer (LAPC): Preliminary feasibility and R0 resection rates from a prospective phase II study.. Journal of Clinical Oncology, 2017, 35, 386-386.	1.6	13
111	Bridging the Gap Between Sorafenib Efficacy and Effectiveness in Advanced Hepatocellular Carcinoma. Oncologist, 2016, 21, 1283-1285.	3.7	0
112	Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma. Cancer Discovery, 2016, 6, 727-739.	9.4	126
113	Intra-pancreatic Distal Bile Duct Carcinoma is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal Adenocarcinoma. Journal of Gastrointestinal Surgery, 2016, 20, 953-959.	1.7	12
114	The Ability to Diagnose Intrahepatic Cholangiocarcinoma Definitively Using Novel Branched DNA-Enhanced Albumin RNA In Situ Hybridization Technology. Annals of Surgical Oncology, 2016, 23, 290-296.	1.5	80
115	Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Journal of Clinical Oncology, 2016, 34, 460-468.	1.6	363
116	PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. Clinical Cancer Research, 2016, 22, 470-478.	7.0	168
117	Phase I study of DKN-01, an anti-DKK1 antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) with advanced biliary cancer.. Journal of Clinical Oncology, 2016, 34, e15603-e15603.	1.6	6
118	Gemcitabine (G) + nab-paclitaxel (nab-P) versus G in patients (pts) with advanced pancreatic cancer (PDAC) after FOLFIRINOX: A single center, retrospective review.. Journal of Clinical Oncology, 2016, 34, 348-348.	1.6	3
119	A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma. Investigational New Drugs, 2015, 33, 128-137.	2.6	40
120	Chemotherapy and antiangiogenics in biliary tract cancer. Lancet Oncology, The, 2015, 16, 882-883.	10.7	2
121	Safety and Efficacy of 70â€“150 Î¼m and 100â€“300 Î¼m Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2015, 26, 516-522.	0.5	62
122	Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. Oncologist, 2015, 20, 1019-1027.	3.7	112
123	A phase II trial of cabozantinib (XL-184) in patients with advanced cholangiocarcinoma.. Journal of Clinical Oncology, 2015, 33, 800-800.	1.6	9
124	A comparative study of circulating biomarkers of anti-VEGF therapy in phase II trials in advanced hepatocellular carcinoma (HCC) patients (pts).. Journal of Clinical Oncology, 2014, 32, 2543-2543.	1.6	1
125	Effect of molecular genotyping to predict outcomes in patients with metastatic pancreatic cancer.. Journal of Clinical Oncology, 2014, 32, 4128-4128.	1.6	3
126	Mismatch repair protein loss and microsatellite instability in cholangiocarcinoma.. Journal of Clinical Oncology, 2014, 32, 237-237.	1.6	6

#	ARTICLE	IF	CITATIONS
127	Effect of baseline characteristics, including antihypertensive therapy, on survival and hypertension during treatment with vascular endothelial growth factor (VEGF) signaling pathway inhibitors (VSP-Is).. Journal of Clinical Oncology, 2014, 32, 9639-9639.	1.6	0
128	A phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors.. Journal of Clinical Oncology, 2014, 32, TPS4157-TPS4157.	1.6	0
129	Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma. Clinical Cancer Research, 2013, 19, 2310-2318.	7.0	276
130	A phase I study ofÂDENSPM (N1, N11-diethylnorspermine) in patients with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2013, 31, 260-260.	1.6	0
131	A phase I study of ganetespib in advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2013, 31, 259-259.	1.6	1